Proprietary AI analyst is now available
- Public Comps
- Taysha GTx
Taysha GTx Valuation Multiples
Discover revenue and EBITDA valuation multiples for Taysha GTx and similar public comparables like Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical and more.
Taysha GTx Overview
About Taysha GTx
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Founded
2019
HQ

Employees
73
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialTaysha GTx Financials
Taysha GTx reported last 12-month revenue of $6M and negative EBITDA of ($140M).
In the same LTM period, Taysha GTx generated $6M in gross profit, ($140M) in EBITDA losses, and had net loss of ($139M).
Revenue (LTM)
Taysha GTx P&L
In the most recent fiscal year, Taysha GTx reported revenue of $10M and EBITDA of ($108M).
Taysha GTx is unprofitable as of last fiscal year, with EBITDA margin of (1103%) and net margin of (1115%).
Financial data powered by Morningstar, Inc.
Taysha GTx Stock Performance
Taysha GTx has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Taysha GTx's stock price is $6.42.
Taysha GTx share price increased by 9.6% in the last 30 days, and by 189.8% in the last year.
Taysha GTx has an EPS (earnings per share) of $-0.38.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 3.7% | 9.6% | 43.6% | 189.8% | $-0.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTaysha GTx Valuation Multiples
Taysha GTx trades at 266.0x EV/Revenue multiple, and (11.7x) EV/EBITDA.
EV / Revenue (LTM)
Taysha GTx Financial Valuation Multiples
As of June 19, 2026, Taysha GTx has market cap of $2B and EV of $2B.
Taysha GTx has a P/E ratio of (13.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Taysha GTx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Taysha GTx Margins & Growth Rates
Taysha GTx decreased revenue by 80% but EBITDA grew by 63% in the last fiscal year.
In the most recent fiscal year, Taysha GTx reported EBITDA margin of (1103%) and net margin of (1115%).
Taysha GTx Margins
Taysha GTx Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Taysha GTx Operational KPIs
Taysha GTx's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.6M for the same period.
Taysha GTx's Rule of 40 is (8856%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Taysha GTx's Rule of X is (8975%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Taysha GTx Competitors
Taysha GTx competitors include Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical, Hanall Biopharma, Idorsia, Mesoblast, Galapagos, Nurix Therapeutics and HUTCHMED (China).
Most Taysha GTx public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 43.8x | 44.3x | (6.7x) | (5.9x) | |||
| 1.0x | 1.1x | (3.8x) | (40.8x) | |||
| 17.7x | 21.2x | (3.8x) | (3.4x) | |||
| 5.5x | 5.4x | 12.0x | 11.7x | |||
| 17.3x | 17.0x | 531.8x | 479.7x | |||
| 12.1x | 12.1x | (59.7x) | (42.9x) | |||
| 109.0x | 15.6x | (27.3x) | (72.0x) | |||
| - | (2.4x) | - | (17.4x) | |||
This data is available for Pro users. Sign up to see all Taysha GTx competitors and their valuation data. Start Free Trial | ||||||
Taysha GTx VC Funding History
Before going public, Taysha GTx raised $125M in total equity funding, across 2 rounds.
Taysha GTx Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Taysha GTx
| When was Taysha GTx founded? | Taysha GTx was founded in 2019. |
| Where is Taysha GTx headquartered? | Taysha GTx is headquartered in United States. |
| How many employees does Taysha GTx have? | As of today, Taysha GTx has over 73 employees. |
| Who is the CEO of Taysha GTx? | Taysha GTx's CEO is Sean P. Nolan. |
| Is Taysha GTx publicly listed? | Yes, Taysha GTx is a public company listed on Nasdaq. |
| What is the stock symbol of Taysha GTx? | Taysha GTx trades under TSHA ticker. |
| When did Taysha GTx go public? | Taysha GTx went public in 2020. |
| Who are competitors of Taysha GTx? | Taysha GTx main competitors include Generate Biomedicines, Sarepta Therapeutics, Viridian Therapeutics, Jafron Biomedical, Hanall Biopharma, Idorsia, Mesoblast, Galapagos, Nurix Therapeutics, HUTCHMED (China). |
| What is the current market cap of Taysha GTx? | Taysha GTx's current market cap is $2B. |
| What is the current revenue of Taysha GTx? | Taysha GTx's last 12 months revenue is $6M. |
| What is the current revenue growth of Taysha GTx? | Taysha GTx revenue growth (NTM/LTM) is 195%. |
| What is the current EV/Revenue multiple of Taysha GTx? | Current revenue multiple of Taysha GTx is 266.0x. |
| Is Taysha GTx profitable? | No, Taysha GTx is not profitable. |
| What is the current EBITDA of Taysha GTx? | Taysha GTx has negative EBITDA and is not profitable. |
| What is Taysha GTx's EBITDA margin? | Taysha GTx's last 12 months EBITDA margin is (2283%). |
| What is the current EV/EBITDA multiple of Taysha GTx? | Current EBITDA multiple of Taysha GTx is (11.7x). |
| How many companies Taysha GTx has acquired to date? | Taysha GTx hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Taysha GTx has invested to date? | Taysha GTx hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Taysha GTx
Lists including Taysha GTx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.